FDA Oncologic Drugs Advisory Committee Meeting

The Committee will discuss AstraZeneca UK Ltd’s supplemental Biologics License Application (sBLA) 761069/S-043 for IMFINZI (durvalumab) injection for the proposed indication, in combination, with chemotherapy as neoadjuvant treatment, followed by IMFINZI as monotherapy after surgery, for the treatment of adult patients with resectable non-small cell lung cancer (NSCLC) in a meeting to be held on FDA White Oak Campus, Silver Spring, MD on July 25 at 9 am. Webcast Link